Jonathan Brammer
Clinical trials sponsored by Jonathan Brammer, explained in plain language.
-
New drug may keep T-Cell lymphoma at bay after transplant
Disease control Recruiting nowThis phase II trial is testing whether the drug ruxolitinib, taken as a daily pill after a stem cell transplant, can help prevent T-cell lymphoma from coming back and reduce the risk of graft-versus-host disease (GVHD). The study will enroll 44 adults with various T-cell lymphoma…
Phase: PHASE2 • Sponsor: Jonathan Brammer • Aim: Disease control
Last updated Jun 24, 2026 04:02 UTC
-
New hope for rare blood cancer: drug trial targets leukemia cells
Disease control Recruiting nowThis study tests a pill called ruxolitinib in 30 adults with a rare type of leukemia (T-LGLL). The drug works by blocking certain enzymes that help cancer cells grow. The main goal is to see if the drug can shrink tumors and improve quality of life, while monitoring side effects.
Phase: PHASE2 • Sponsor: Jonathan Brammer • Aim: Disease control
Last updated Jun 17, 2026 12:08 UTC